company mission on aging, immune restoration, and age-related disease treatment
Very little changed between January 17, 2021 and January 25, 2022. Rejenevie kept the same core thesis: aging is close to universal, it degrades immune function, it raises systemic inflammation, and that combination increases risk for major age related diseases. The company also kept the same practical claim about what it wants to do with that thesis, develop therapeutics for immune restoration and for diseases tied to aging. The shift is mostly rhetorical. In 2021, the company said aging is "effectively universal" and associated with immune weakening and inflammation. In 2022, it sharpened that into the claim that aging functionally behaves like a universal disease process. That is a stronger framing, but not a new mission. It reads more like a tighter way to position the same program than a real change in scientific direction. Evidence is thin because the record here covers only two website snapshots, one year apart, and both say almost the same thing. We do not see a new target, modality, disease priority, or clinical claim. The safest reading is continuity with slightly more explicit disease framing.